FDA panel issues mixed decision on quetiapine in depression and anxiety

JAMA. 2009 May 27;301(20):2081-2. doi: 10.1001/jama.2009.708.
No abstract available

Publication types

  • News

MeSH terms

  • Antipsychotic Agents / adverse effects*
  • Antipsychotic Agents / therapeutic use
  • Anxiety Disorders / drug therapy
  • Depressive Disorder, Major / drug therapy
  • Dibenzothiazepines / adverse effects*
  • Dibenzothiazepines / therapeutic use
  • Drug Approval
  • Humans
  • Quetiapine Fumarate
  • United States
  • United States Food and Drug Administration*

Substances

  • Antipsychotic Agents
  • Dibenzothiazepines
  • Quetiapine Fumarate